Actually, that was an 'exploratory' end point as per their presentation
Primary:
Safety and tolerability
Secondary:
• Characterize PK/PD*
parameters
Exploratory:
• Physical and visual skin and
scar assessments
So contrary to what is being said here by some posters, they did meet the end points!
Ann: PXS Announces Encouraging Results from Phase 1c Scar Study, page-9
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SNT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $28.65M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 519110 | 2.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.4¢ | 131428 | 2 |
View Market Depth
| Last trade - 10.39am 03/07/2024 (20 minute delay) ? |
| SNT (ASX) Chart |
Day chart unavailable